Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

Trump administration demands lower U.S. prices on drugs like Mounjaro, forcing the pharmaceutical company to raise them in ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

It comes as President Donald Trump pressures drugmakers to lower U.S. drug prices while hiking them abroad under a policy ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...